Venture Capital/Healthtech, SaaS, semiconductors
Endiya Partners logo

Endiya Partners

Seed fund research profile

Endiya Partners is a thesis-led early-stage investor focused on healthcare, enterprise technology, semiconductors, AI, security and intelligent mobility. The firm positions itself as an operator VC, working closely with founders on product, hiring, market access, follow-on funding and capital planning.

At a glance

Founded
2016
Footprint
Hyderabad
Stage
Seed

Research profile

Read the manager in sequence.

Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.

Investment lens

Endiya Partners uses a seed approach across Healthtech, SaaS, semiconductors.

Current evidence

Endiya reported that it was doubling down on deeptech, healthcare and enterprise software for its ₹800 crore Fund III; IFC's public portfolio disclosure names Grip Invest, AquaExchange, BluJ and Cell Propulsion.

Strategy

Seed

Sector focus

Healthtech, SaaS, semiconductors

AIF structure context

Indian venture capital and angel-fund strategies are commonly structured as Category I AIFs. Verify the specific vehicle and registration before investing.

Current signal

Endiya reported that it was doubling down on deeptech, healthcare and enterprise software for its ₹800 crore Fund III; IFC's public portfolio disclosure names Grip Invest, AquaExchange, BluJ and Cell Propulsion.

Investor questions

Endiya Partners research questions

What is Endiya Partners's investment strategy?

Endiya Partners is covered in Rupeia's venture capital research universe. The current public record describes the strategy as Seed, with a sector focus of Healthtech, SaaS, semiconductors. The profile should be read with the linked source trail and Typical route: Category I AIF context.

What portfolio evidence is available for Endiya Partners?

The profile displays only company or asset names attributable to Endiya Partners in the reviewed public sources: Darwinbox (seed), SigTuple, Kissht (early). It does not represent a complete current portfolio unless the manager has published one.

What is known about Endiya Partners's performance or track record?

Fund II closed at ₹500 crore, with reported initial cheques of $1–1.5M and $4–5M follow-ons. Inc42 reports that portfolio companies raised up to $50M in follow-on rounds from later-stage investors; this is a portfolio signal rather than a disclosed fund return. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.

What are Endiya Partners's fund size, fees and minimum investment?

Public fund size: Fund II final close ₹500 crore; IFC disclosed an equity commitment of up to $10M. The public record identifies a Fund III vehicle but not a final close figure.. Public terms or access information: Seed and pre-Series A, focused on B2B technology, healthcare and selected consumer services. The manager describes approximately 18 investments over 2.5 years and initial rounds up to ₹20–25 crore in its newer strategy.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.

Who is on Endiya Partners's investment team?

The current source record names Sateesh Andra, Ramesh Byrapaneni. Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.

What risks should be reviewed before investing with Endiya Partners?

Review stage concentration, follow-on reserves, company failure rates, dilution, exit timing and the gap between paper valuations and realised distributions. The current open diligence point is: Fund III status.

What is the latest public update on Endiya Partners?

2025-11-10: Endiya reported that it was doubling down on deeptech, healthcare and enterprise software for its ₹800 crore Fund III; IFC's public portfolio disclosure names Grip Invest, AquaExchange, BluJ and Cell Propulsion.

Next step

Need this manager reviewed against your mandate?

Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.

Request independent diligence →